PyL PET/CT for High-Risk Prostate Cancer
PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer
Recruiting
Phase 2
Interventional Study
Prostate Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Male
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 184 (estimated)
- Sponsor
- Hoag Memorial Hospital Presbyterian · Other
Who this trial is looking for
This trial is looking for men with high-risk prostate cancer or a return of prostate cancer after treatment. Participants will have a special imaging test to see how well their cancer is responding to treatment.
Are You a Good Fit for This Trial?
You may be able to join if
- I am a man aged 18 or older.
- I have been diagnosed with prostate cancer.
- I have high-risk prostate cancer or a return of prostate cancer after treatment.
- I have had imaging tests that showed no signs of cancer in the last 3 months.
You may not be able to join if
- I have a medical condition that could make participating unsafe.
- I weigh more than 450 pounds.
- I have changed my cancer treatment since my last imaging test.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The standard of care imaging of prostate cancer metastases recommended by the National Comprehensive Cancer Network (NCCN), CT of the chest/abdomen/pelvis and bone scan, may be suboptimal. PyL is a novel PET tracer designed to detect prostate specific membrane antigen (PSMA) expressed on prostate cancer cells. PyL PET/CT may provide improved evaluation of clinically significant metastases in patie…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Male ≥ 18 years of age.
2. Histologically confirmed adenocarcinoma of the prostate
3. Patients meet one of the follow criteria:
Cohort 1: High risk prostate cancer (PSA \>10, Gleason 8-10, or clinical stage \>T2c) and planned prostatectomy or radiation therapy or Cohort 2: B…
Contacts